Oct. 15 - Lilly bolsters GLP-1 pill’s case, Arch dives into hair loss and $361M for ADCs
A regenerative therapy for hair loss attracts a mega-fundraising round; Cancer drug startup Tubulis raises $361 million for ADCs; Biotech startups are built on venture capital. Track funding rounds here.; Kailera nets $600M more to advance Zepbound-like obesity drug
Join the world’s largest labor and employment law firm to learn how to guard against unfair competition & protect talent and trade secrets.
Register: Littler Webinar.
Some Wall Street analysts have questioned orforglipron’s sales outlook in obesity, but see great potential in diabetes, where on Wednesday it succeeded in two more late-stage trials.
Backed by GV and Arch Venture Partners, Pelage Pharmaceuticals is advancing a first-of-its-kind topical gel designed to activate dormant hair follicle stem cells.
The German biotech banked one of the larger funding rounds this year to support an ovarian and non-small cell lung cancer drug that’s being showcased at a medical meeting on Sunday.
Among the largest private biotech funding rounds this year, the financing will support global trials of an obesity shot that just succeeded in late-stage testing in China.
